From Surf Wiki (app.surf) — the open knowledge base

Aleph-7

Field	Value
image	Aleph-7.svg
image_class	skin-invert-image
routes_of_administration	Oral
class	Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen; Monoamine oxidase inhibitor; Reversible inhibitor of MAO-A
ATC_prefix	None
duration_of_action	15–30 hours
CAS_number	207740-16-7
PubChem	11197521
ChemSpiderID	9372590
UNII	RB42O7HM6C
ChEMBL	341318
synonyms	ALEPH-7; DOT-7; 4-Propylthio-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-propylthioamphetamine; 4-PrS-DMA
IUPAC_name	1-(2,5-dimethoxy-4-propylsulfanylphenyl)propan-2-amine
C	14	H=23	N=1	O=2	S=1
SMILES	CCCSC1=C(C=C(C(=C1)OC)CC(C)N)OC
StdInChI	1S/C14H23NO2S/c1-5-6-18-14-9-12(16-3)11(7-10(2)15)8-13(14)17-4/h8-10H,5-7,15H2,1-4H3
StdInChIKey	XHWDHFUBCVWXDZ-UHFFFAOYSA-N

| Drugs.com =

| elimination_half-life =

Aleph-7, or ALEPH-7, also known as 4-propylthio-2,5-dimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It is one of the Aleph series of compounds.

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists Aleph-7's dose as 4 to 7mg orally and its duration as 15 to 30hours. The effects of Aleph-7 have been reported to include strangeness, slight visual changes, intense but difficult to describe altered states of consciousness, everything feeling "preprogrammed", emotional changes, negative reactions, unwillingness to take the drug again, relaxation, and paresthesia, among others. It was said to produce a "Beth state", defined as a state of uncaring, anhedonia, and emotionlesssness. Many other drugs are also said to have a touch of such a state, but Aleph-7 to have more of it than most.

It is a potent agonist of the serotonin 5-HT2A receptor, with an of 2.2 to 7.6nM and an of 116 to 189%. The drug is also a weak monoamine oxidase inhibitor (MAOI), specifically a reversible inhibitor of MAO-A (RIMA), with an of 2.4μM. The chemical synthesis of Aleph-7 has been described.

Aleph-7 was first described in the scientific literature by Shulgin in 1981. Subsequently, it was described in greater detail by Shulgin PiHKAL in 1991. The drug was encountered as a novel designer drug in Europe in 2005. It is a controlled substance in Canada under phenethylamine blanket-ban language.

References

{{CitePiHKAL https://erowid.org/library/books_online/pihkal/pihkal007.shtml
(August 2023). "Structure-Activity Assessment and In-Depth Analysis of Biased Agonism in a Set of Phenylalkylamine 5-HT2A Receptor Agonists". ACS Chem Neurosci.
(2019). "Amphetamine Derivatives as Monoamine Oxidase Inhibitors". Front Pharmacol.
(April 2005). "Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling". J Med Chem.
(1980). "Burger's Medicinal Chemistry". Wiley.
(1982). "Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs". Springer Berlin Heidelberg.
(2014). "New phenethylamines in Europe". Drug Test Anal.
"Controlled Drugs and Substances Act".

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

5-ht2a-agonists designer-drugs dox-(psychedelics) monoamine-oxidase-inhibitors propylthio-compounds pihkal psychedelic-phenethylamines serotonin-receptor-modulators

Want to explore this topic further?

Ask Mako anything about Aleph-7 — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report